-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zipalertinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zipalertinib in Solid Tumor Drug Details: zipalertinib is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BR-9003 in Smoking Cessation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BR-9003 in Smoking CessationDrug Details:BR-9003 is under development for the treatment of smoking cessation. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ANCA Associated Vasculitis in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ANCA Associated Vasculitis in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Drug Details: The therapeutic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Crohn’s Disease (Regional Enteritis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ustekinumab Biosimilar in Crohn's Disease (Regional Enteritis) Drug Details:Ustekinumab biosimilar (FYB-202) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKMO-3415 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CKMO-3415 in Obesity Drug Details: CKMO-3415 is under development for the treatment of obesity....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zipalertinib in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Zipalertinib in Non-Small Cell Lung Cancer Drug Details:zipalertinib is under development for the treatment of non-small...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABD-3001 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ABD-3001 in Myelodysplastic Syndrome Drug Details:ABD-3001 (sefaldin) is under development for the treatment of acute myelocytic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Radgocitabine in Relapsed Acute Myeloid Leukemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radgocitabine in Relapsed Acute Myeloid Leukemia Drug Details: Radgocitabine (DFP-10917) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAS-0728 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAS-0728 in Non-Small Cell Lung CancerDrug Details:TAS-0728 is under development for the treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YH-002 in Thymic Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.YH-002 in Thymic CarcinomaDrug Details:YH-002 is under development for the treatment of advanced solid malignancies including...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.